会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 04 月 21 日(星期五) 至 04 月 27 日(星期四)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或或通过公司邮箱 ir@kexing.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 科兴生物制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 22 日发 布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营 成果、财务状况，公司计划于 2023 年 04 月 28 日下午 15:00-16:30 举行 2022 年 度业绩说明会，就投资者关心的问题进行交流。 证券代码：688136 证券简称：科兴制药 公告编号：2023-022 科兴生物制药股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 04 月 28 日(星期五) 下午 15:00-16:30 会议召开地点： ...

证券代码: 688136 证券简称：科兴制药 科兴生物制药股份有限公司投资者关系活动记录表 编号：2022-003 | --- | --- | |----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码: 688136 证券简称：科兴制药 科兴生物制药股份有限公司投资者关系活动记录表 编号：2022-004 | --- | --- | |-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：688136 证券简称：科兴制药 公告编号：2022-057 科兴生物制药股份有限公司 关于参加山东辖区上市公司 2022 年度 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，构建和谐投资者关系，科兴生物制药股 份有限公司（以下简称"公司"）将参加由山东证监局、山东上市公司协会联合 举办的"山东辖区上市公司 2022 年度投资者网上集体接待日活动"，现将有关 事项公告如下： 本次集体接待日活动将通过全景网平台以线上交流的方式举行，投资者可以 登录全景网"投资者关系互动平台"网站（http://rs.p5w.net）参与本次活动。 活动时间为 2022 年 11 月 16 日（星期三）下午 14:00-16:00。 届时公司董事、总经理赵彦轻先生及财务总监、董事会秘书王小琴女士将通 过网络在线交流问答的形式，与投资者进行沟通和交流，欢迎广大投资者积极参 与。 特此公告。 科兴生物制药股份有限公司董事会 2022 年 11 月 15 日 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with total revenue reaching RMB 1.5 billion, representing a year-on-year growth of 25%[12]. - The company's revenue for the first half of the year was approximately CNY 629.38 million, representing a 5.70% increase compared to CNY 595.42 million in the same period last year[18]. - The company has set a performance guidance of RMB 3 billion in revenue for the full year 2022, reflecting a growth target of 25%[12]. - The company achieved total operating revenue of 629.38 million yuan in the first half of 2022, an increase of 5.70% year-on-year[73]. - The company reported a revenue increase of 15% year-over-year for the first half of 2022, reaching $500 million[112]. - Future guidance indicates a projected revenue growth of approximately 10% for the next fiscal year[192]. Profitability - Net profit attributable to shareholders decreased by 95.23% to CNY 2.90 million from CNY 60.75 million year-on-year[18]. - The net profit attributable to the parent company was 2.90 million yuan, a decrease of 95.23% year-on-year, while the net profit after deducting non-recurring gains and losses was 3.38 million yuan, down 93.62% year-on-year[56]. - The company reported a significant decrease in net profit for the first half of 2022, with a loss of CNY 7,014,859.85, compared to a profit of CNY 46,980,120.04 in the same period of 2021[182]. - The company reported a net profit of 19,870,065.00 for the current period, unchanged from the previous year[193]. Research and Development - The company increased its R&D investment to 12.61% of revenue, up 5.48 percentage points from 7.13% in the same period last year[18]. - The total R&D investment for the period reached approximately ¥79.39 million, representing an 87.11% increase compared to ¥42.43 million in the same period last year[42]. - The company reported a significant increase in R&D personnel and activities, with R&D expenses rising by 87.11% year-on-year[19]. - The company has established a comprehensive R&D system covering drug discovery, preclinical research, clinical research, and industrialization, supported by various technology platforms[30]. - The company is actively expanding its product pipeline, focusing on new indications and product iterations in the recombinant protein sector[30]. - The company has initiated 17 research pipelines for gene-engineered vaccines targeting both pet and economic animals, in line with the growing market for innovative animal vaccines[66]. Market Expansion - User data indicates that the company has expanded its customer base by 15%, now serving over 1 million active users[12]. - The company is planning to expand its market presence in Southeast Asia, targeting a 20% market share by the end of 2023[12]. - The company is focusing on the international market for innovative drugs, particularly in response to global demand for COVID-19 treatments[37]. - The company plans to enter two new international markets by the end of 2022, aiming for a revenue contribution of $30 million from these markets[114]. - The company has established wholly-owned subsidiaries in Singapore, Mexico, and Egypt to enhance its international market presence[61]. Strategic Initiatives - The company has completed a strategic acquisition of a biotech firm for RMB 500 million, enhancing its R&D capabilities[12]. - The company is exploring acquisition opportunities to enhance its product portfolio, with a budget of $200 million allocated for potential acquisitions[112]. - The company has emphasized its commitment to corporate governance and transparency in its operations[12]. - The company is committed to improving its operational efficiency through strategic investments in technology and infrastructure[192]. Risks and Challenges - The company has identified potential risks including regulatory changes and market competition, which could impact future performance[12]. - The company faces risks related to the loss of core technical personnel, which could impact operational stability[69]. - The company relies heavily on overseas suppliers for key raw materials, which poses a risk of supply disruptions or price increases[70]. - The company faces risks from intensified industry competition and regulatory challenges, which could adversely affect its operations[71][72]. Environmental Compliance - The company has been recognized as a provincial-level technology center and has established several engineering technology centers, enhancing its innovation capabilities[33]. - The company has established an emergency response plan for environmental incidents, investing in emergency materials and training personnel to handle potential wastewater treatment facility risks[102]. - The company has obtained pollution discharge permits from relevant environmental authorities, including Shenzhen and Jinan, ensuring compliance with environmental regulations[101]. - The company has committed to minimizing pollutant discharge increases with new projects to achieve sustainable economic and environmental development[101]. Shareholder Commitments - The company’s major shareholders have made commitments regarding the lock-up period for shares, ensuring stability in stock performance post-IPO[110]. - The company will ensure that the repurchase of shares does not lead to a violation of listing conditions or trigger mandatory tender offer obligations for controlling shareholders[116]. - The company has established a profit distribution policy that aligns with regulatory requirements, focusing on cash dividends and stock dividend conditions[119]. - The company will publicly explain any failure to fulfill commitments and apologize to shareholders if it does not comply with the profit distribution policy[123].

2022 年第一季度报告 证券代码：688136 证券简称：科兴制药 科兴生物制药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 审计师发表非标意见的事项 □适用 √不适用 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 一、 主要财务数据 第一季度财务报表是否经审计 □是 √否 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年 | | | --- | --- | --- | --- | | | | 同期增减变动幅 | | | | | 度(%) | | | 营业收入 | | 269,714,119.70 | -2.65 | | 归属于上市公司股东的净利润 | | 29,109,430.39 | -37.49 | ...

Financial Performance - In 2021, the company achieved a net profit attributable to shareholders of 96,463,914.26 RMB, with the parent company net profit at 68,930,132.55 RMB, resulting in a distributable profit of 62,037,119.29 RMB after statutory reserve allocation[6]. - The cumulative distributable profit reached 162,775,719.79 RMB by the end of 2021[6]. - The company's operating revenue for 2021 was CNY 1,285,171,728.90, representing a year-over-year increase of 5.32% compared to CNY 1,220,289,989.43 in 2020[20]. - Net profit attributable to shareholders decreased by 30.67% to CNY 96,463,914.26 from CNY 139,137,168.72 in the previous year[20]. - The basic earnings per share (EPS) fell by 47.31% to CNY 0.49, down from CNY 0.93 in 2020[22]. - The net profit after deducting non-recurring gains and losses was CNY 47,052,294.66, a significant drop of 65.85% from CNY 137,761,642.85 in 2020[20]. - The company reported a net profit of CNY 44,102,316.74 in the first quarter, which decreased to CNY -18,298,361.31 in the fourth quarter[26]. - The company reported a total revenue of 725.46 million RMB for the year, with a significant increase in R&D expenses amounting to 122.95 million RMB, representing a growth of 87.5% compared to the previous year[80]. - The company reported a total revenue of 1,128.96 million, reflecting a significant growth compared to previous periods[175]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion for the fiscal year 2021, representing a 20% increase year-over-year[178]. Research and Development - The company’s R&D expenses increased significantly, accounting for 9.57% of operating revenue, up from 4.93% in 2020[22]. - R&D expenditure reached 122.95 million yuan, an increase of 104.54% compared to 2020[39]. - The company achieved total R&D expenditure of approximately ¥122.95 million in the reporting period, representing a year-on-year increase of 104.54%[72]. - The number of R&D personnel increased by 14.12% to 194, with the proportion of R&D staff in the total workforce rising to 13.87% from 12.04%[82]. - The R&D team has seen a 93.75% increase in personnel with master's degrees and an 85.71% increase in those with doctoral degrees, indicating a focus on high-quality talent[82]. - The company has established a comprehensive biopharmaceutical R&D innovation system, including three major biotechnological foundations[61]. - The company is actively developing new products, including a novel oral antiviral drug SHEN26, currently in preclinical work[44]. - The company has completed non-clinical research for several new drug projects, including human interferon α1b and α2b formulations[138]. - The company plans to conduct Phase I clinical trials domestically and multi-center Phase II and III clinical trials overseas for a new oral COVID-19 drug[155]. - The company is investing heavily in R&D, with a budget allocation of 172.28 million for new technologies and product development[175]. Market and Product Development - The company expanded its marketing coverage to over 19,000 terminals, an increase of nearly 3,000 compared to the end of 2020[35]. - The market share of the product "Sairuo Jin" ranked first in the domestic short-acting human interferon market at 30.81%[35]. - The company has obtained exclusive commercialization rights for multiple products in over 30 countries and regions, enhancing its international market presence[34]. - The company has successfully exported products to over 30 countries, including Brazil, the Philippines, and Indonesia[56]. - The company aims to become a leader in high-quality biopharmaceuticals, with a mission focused on "lean pharmaceuticals, lean medication, and safeguarding health"[49]. - The company is focused on enhancing its core technology platforms through innovation and the development of new products and technologies[68]. - The company is actively expanding its product line and continuously enhancing its R&D capabilities to maintain competitiveness in the biopharmaceutical industry[136]. - The company is exploring potential acquisitions to bolster its technology portfolio, with a budget of 200 million RMB allocated for this purpose[183]. Governance and Compliance - The company operates under the supervision of the China Securities Regulatory Commission and adheres to the relevant laws and regulations[11]. - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and management, ensuring clear responsibilities and effective operation[164]. - The board of directors comprises 7 members, including 3 independent directors, who fulfill their duties diligently and independently[165]. - The supervisory board consists of 3 members, including 1 employee representative, ensuring effective oversight of the company's operations and financial status[166]. - The company has implemented a system for managing insider information, ensuring timely and accurate disclosure of information to all shareholders[168]. - There were no significant differences between the company's governance practices and the regulations set by the China Securities Regulatory Commission[168]. - The company reported no instances of the controlling shareholder occupying company funds or assets[167]. Financial Risks and Management - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company is primarily reliant on overseas suppliers for key raw materials, which poses supply risks amid global economic uncertainties[91]. - The company faced risks related to core technology personnel turnover, which could impact operational stability[90]. - The company reported a significant increase in management expenses by 30.77% due to the hiring of talented management personnel and increased operational costs[99]. - The company’s financial data indicates a reliance on collateralized loans for fixed and intangible assets, highlighting potential financial constraints[127]. Customer Engagement and Satisfaction - The company reported a user growth rate of 40% year-over-year, indicating strong market demand and customer acquisition[175]. - Customer satisfaction scores have improved by 20%, reflecting the effectiveness of recent service enhancements[175]. - Customer satisfaction ratings improved to 90%, reflecting the success of recent service enhancements[178]. - Customer satisfaction ratings improved to 85%, reflecting the success of recent service enhancements[183].

证券代码：688136 证券简称：科兴制药 公告编号：2021-043 科兴生物制药股份有限公司 关于参加山东辖区上市公司投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，构建和谐投资者关系，科兴生物制药股 份有限公司（以下简称"公司"）将参加由中国证券监督管理委员会山东监管局、 山东上市公司协会联合举办并由深圳市全景网络有限公司承办的"山东辖区上市 公司投资者网上集体接待日活动"，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台举行，投资者可以登录"全景·路演天下"网站（http://rs.p5w.net） 参与本次活动。活动时间为 2021 年 11 月 16 日（星期二）下午 14:00-16:00。 届时公司财务总监、董事会秘书王小琴女士及证券事务代表闫龙英女士将通 过网络在线交流问答的形式，与投资者进行沟通和交流，欢迎广大投资者积极参 与。 特此公告。 科兴生物制药股份有限公司董事会 2021 年 11 ...

Revenue and Profit - The company's revenue for Q3 2021 was ¥300,801,193.89, representing a decrease of 7.51% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2021 was ¥14,561,979.44, down 36.51% year-over-year[5]. - The net profit excluding non-recurring gains and losses for the year-to-date period was ¥65,350,655.97, a decrease of 44.19% compared to the previous year[5]. - Total operating revenue for the first three quarters of 2021 reached ¥896,224,612.15, a slight increase from ¥891,398,225.86 in the same period of 2020, representing a growth of approximately 0.3%[22]. - Net profit for the third quarter of 2021 was ¥75,311,132.71, down from ¥117,483,107.20 in the same quarter of 2020, indicating a decline of approximately 36%[24]. - Earnings per share for the third quarter of 2021 was ¥0.38, compared to ¥0.79 in the same quarter of 2020, showing a decrease of about 52%[25]. Research and Development - Research and development expenses for Q3 2021 totaled ¥33,238,899.27, an increase of 153.95% year-over-year, accounting for 11.05% of revenue[6]. - The company increased its R&D investment significantly, with a year-to-date increase of 78.54% in R&D expenses compared to the previous year[12]. - Research and development expenses for the third quarter of 2021 totaled ¥75,667,529.40, significantly higher than ¥42,380,754.28 in the same quarter of 2020, marking an increase of approximately 78.6%[23]. - The company has ongoing investments in research and development, with a focus on new product development and market expansion strategies[15]. Assets and Liabilities - Total assets as of the end of the reporting period were ¥2,605,624,105.01, reflecting a growth of 10.10% from the end of the previous year[6]. - As of September 30, 2021, total assets amounted to CNY 2.61 billion, an increase from CNY 2.37 billion at the end of 2020[19]. - The total liabilities were CNY 500.67 million, compared to CNY 440.70 million at the end of 2020, indicating an increase in financial obligations[19]. - Total liabilities as of the end of the third quarter of 2021 amounted to ¥716,088,324.79, compared to ¥536,495,748.20 at the end of the previous year, representing an increase of about 33.5%[23]. - The total non-current liabilities amounted to ¥215,421,722.85, compared to ¥95,794,825.78 in the previous year, indicating a significant increase of about 125.5%[23]. - Total liabilities amounted to ¥536,495,748.20, with a year-on-year increase of ¥31,752,978.24[31]. - The company reported a total asset value of ¥2,366,616,447.71, reflecting a slight decrease of ¥31,752,978.24 compared to the previous period[31]. Cash Flow and Financing - Cash inflows from operating activities for the first three quarters of 2021 were ¥942,992,734.12, compared to ¥818,003,174.06 in the same period of 2020, indicating an increase of about 15.3%[26]. - The cash inflow from financing activities was 355,109,057.03 RMB, an increase from 288,716,036.85 RMB in the previous year[27]. - The company paid 243,192,345.52 RMB in debt repayment, which is higher than 204,970,750.03 RMB from the previous year[27]. - The total cash outflow from investing activities was 2,048,263,375.70 RMB, significantly higher than 104,294,355.32 RMB in the same period last year, resulting in a net cash outflow of -574,679,902.47 RMB from investing activities[27]. - The company received cash from investment recovery amounting to 1,396,000,000.00 RMB, indicating strong investment performance[27]. Shareholder Information - The company reported a total of 13,799 common shareholders at the end of the reporting period[13]. - The largest shareholder, Shenzhen Keyi Pharmaceutical Holdings, holds 66.32% of the shares, totaling 131,778,347 shares[13]. Other Financial Metrics - The weighted average return on equity decreased to 0.77%, down 2.08 percentage points year-over-year[6]. - The company reported a tax expense of ¥3,870,689.03 for the third quarter of 2021, down from ¥19,054,484.31 in the same quarter of 2020, representing a decrease of approximately 79.7%[24]. - The company’s retained earnings were reported at ¥352,232,308.28, unchanged from the previous period[31]. - The capital reserve stood at ¥1,266,228,335.40, consistent with prior reporting periods[31]. - The company has not reported any changes in preferred shares or perpetual bonds in the current financial period[31].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2021, representing a 25% growth compared to the same period last year[11]. - Revenue for the first half of the year increased by 5.16% year-on-year, with domestic sales growing steadily while overseas sales declined due to the pandemic[19]. - The company achieved a total revenue of 718,983,951.80 RMB for the first half of 2021, with a net profit of 138,685,017.09 RMB, reflecting a significant increase in performance[53]. - The company achieved total revenue of 595.42 million yuan, a year-on-year increase of 5.16%[64]. - The net profit attributable to the parent company was 60.75 million yuan, a year-on-year decrease of 35.75%[64]. - The company reported a total of 210,000 shares held by Feng Zhong, with no changes in ownership during the reporting period[160]. - The company reported a total comprehensive income of CNY 60,749,153.27 for the first half of 2021[196]. Research and Development - The company has allocated 200 million RMB for research and development in new technologies, focusing on mRNA vaccine platforms and antibody therapies[11]. - R&D investment as a percentage of operating revenue rose to 7.13%, an increase of 1.96 percentage points compared to the previous year[18]. - Research and development (R&D) expenses amounted to approximately ¥42.43 million, representing a 44.85% increase compared to ¥29.29 million in the previous period[46]. - The company is advancing its R&D pipeline, focusing on new proteins, antibodies, and nucleic acid drugs, with ongoing clinical projects for erythropoietin injection[27]. - The company has established a comprehensive R&D system for biopharmaceuticals, focusing on recombinant proteins, new antibodies, and nucleic acid drugs, with a complete innovation capability from drug discovery to industrialization[33]. - The company is focusing on the development of new protein and antibody technologies, as well as mRNA therapies, which are gaining traction in the global market[39]. - The company has introduced a significant number of high-level R&D talents, with a 53.33% increase in personnel with master's degrees or higher compared to the previous year[47]. Market Position and Expansion - User data indicates that the company has expanded its customer base by 30%, reaching over 2 million active users by the end of June 2021[11]. - The company has provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 30% based on current market trends and product demand[11]. - New product development efforts have led to the successful launch of two innovative vaccines, contributing to a 15% increase in market share within the biopharmaceutical sector[11]. - The company is actively pursuing market expansion strategies, targeting Southeast Asia and Europe, with plans to establish partnerships with local distributors by Q4 2021[11]. - The company has established a solid market position with a 30.81% market share for its short-acting human interferon product, ranking first in the industry[28]. - The company is advancing its R&D projects, including human erythropoietin injection, with clinical trials progressing steadily[67]. Financial Management and Investments - The company has implemented cost-cutting measures that are projected to reduce operational expenses by 10% over the next year, improving overall profitability[11]. - The company has allocated a maximum of CNY 550 million for cash management of idle raised funds, which can be rolled over within a 12-month period[144]. - The company has invested CNY 14,000 million in structured deposits with Bank of China, with an expected annual yield of 1.3% to 3.81%[146]. - The company has successfully recovered principal and interest from all structured deposits and financial products as of the reporting date[146]. - The company has completed 100% of the investment for working capital, amounting to RMB 39.59 million[143]. Risk Management - The company has identified potential risks related to regulatory changes and market competition, which are detailed in the risk factors section of the report[11]. - The company is facing risks related to material supply, R&D failures, and industry competition, which may impact operations[74][75]. - The company is committed to strict quality management in compliance with national regulations to mitigate drug quality control risks[74]. Shareholder Commitments and Governance - The board has approved a share buyback program worth 100 million RMB to enhance shareholder value and support stock price stability[11]. - The company has committed to not transferring or entrusting the management of shares held before the IPO for 36 months from the date of listing[109]. - The company will implement stock repurchase measures if the stock price stabilization conditions are triggered, with a minimum repurchase amount not less than 5% of the last audited net profit for the previous accounting year[114]. - The company has established a plan to ensure compliance with these commitments, including potential legal actions against violators[109]. - The company has pledged to compensate investors for losses resulting from any false statements or omissions in the prospectus within thirty days of liability establishment[123]. Environmental Compliance - Kexing Biopharmaceutical Co., Ltd. and its subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. are listed as key pollutant discharge units by environmental protection authorities[98]. - The company has established an emergency response plan for environmental incidents, which includes procurement of emergency materials and training for staff[103]. - Kexing Biopharmaceutical has obtained pollution discharge permits from relevant environmental authorities, ensuring compliance with environmental regulations[101].